US20200046627A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
US20200046627A1
US20200046627A1 US16/496,291 US201816496291A US2020046627A1 US 20200046627 A1 US20200046627 A1 US 20200046627A1 US 201816496291 A US201816496291 A US 201816496291A US 2020046627 A1 US2020046627 A1 US 2020046627A1
Authority
US
United States
Prior art keywords
vitamin
skin
composition according
acid
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/496,291
Other languages
English (en)
Inventor
Teo ALBARANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joyderma Ag
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58464118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20200046627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of US20200046627A1 publication Critical patent/US20200046627A1/en
Assigned to JOYDERMA AG reassignment JOYDERMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALBARANO, Teo
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W36/00—Hand-off or reselection arrangements
    • H04W36/0005—Control or signalling for completing the hand-off
    • H04W36/0055—Transmission or use of information for re-establishing the radio link
    • H04W36/0058—Transmission of hand-off measurement information, e.g. measurement reports
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18

Definitions

  • the present invention is directed towards new compositions comprising a synergistic combination of a vitamin D or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in the prevention and/or treatment of skin photodamage, in particular in the prevention and/or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.
  • a lipid based colloidal carrier system preferably lipid based vesicles such as liposomes, niosomes, tranferosomes
  • topical formulations thereof as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in
  • Skin disorders according to ICD-10 include (a) group of conditions in which the skin becomes inflamed, forms blisters, and becomes crusty, thick, and scaly (including eczema causing burning and itching, occurring over a long period of time), (b) any type of skin inflammation, (c) an inflammatory process affecting the skin (with signs of red rash, itching, and blister formation), e.g. contact dermatitis, atopic dermatitis, seborrheic dermatitis and psoriasis, and (d) pruritic papulovesicular dermatitis occurring as a reaction to many endogenous and exogenous agents.
  • Photo damage of the skin is characterized as a skin disorder due to radiation of ultraviolet A (UVA) and ultraviolet B (UVB) with the following major symptoms: skin atrophy, skin dyspigmentation (patches/spots), photodermatitis (erythema: inflamed, reddened skin), telangiectasia, (couperose) and actinic keratosis.
  • UVB with a wavelength of 280-315 nm provides the energy the skin needs to make vitamin D3, but is also a primary mutagen that penetrates through the epidermal layer of the skin, resulting in DNA mutations, potentially leading to skin cancer (non melanoma skin cancer (NMSC) and melanoma).
  • UVA with a wavelength of 315-400 nm is able to penetrate deeper into the skin as compared to UVB rays and thus may damage both the epidermal and dermal layers. With constant UVA exposure, the size of the dermis layer will be reduced, causing an atrophy of the skin.
  • Potential damages include dilated or broken blood vessels, causing telangiectasia (couperose) or indirect damages to cellular DNA as well as lipids and proteins of the skin barrier through the generation of reactive oxygen species (ROS), which are cytotoxic.
  • ROS reactive oxygen species
  • Both UVA and UVB exposure can also lead to inflammation and vasodilation, which is clinically manifested as telangiectasia, (couperose) and photodermatitis (erythema resulting in inflamed and reddened skin), Dyspigmentation (patches/spots) and other skin disorders [see e.g. 1, 2, 3].
  • ROS reactive oxygen species
  • NO Nitric oxide
  • O 2 oxygen
  • O 2 peroxynitrite
  • Peroxynitrite and its degradation from the reaction with CO 2 are highly cytotoxic throughout the oxidation of lipids, proteins and DNA in the epidermis.
  • Vitamin D is a group of fat-soluble vitamins with vitamin D 3 (or cholecalciferol) and vitamin D 2 (or ergocalciferol) being the most important representatives in humans.
  • vitamin D3 is obtained by photolysis of 7-dehydrocholesterol (or 7-DHC, found prominently in the stratum spinosum and stratum basale of the upper layer of the skin at about 25-50 ug/cm 2 ) by UVB [see e.g. 4-7, FIG. 1 ] to obtain the precursor previtamin D3, which is then thermally isomerized to give vitamin D3. It is known that the vitamin D3 production throughout the skin decreases dramatically with aging (up to 75 wt % at the age of 70).
  • Vitamin D3 and its precursors and derivatives are biologically very active.
  • the precursor 7-DHC has the capability to bind the reactive oxigenes species NO and thus avoids overproduction of cytotocic peroxynitrite in the upper parts of the skin, preventing the vicious circle (circulus vitiosus) of skin inflammation with cellular skin damages [ FIGS. 2, 3 ].
  • Vitamin D3 plays a role in many processes, including bone mineralization, bone growth and bone remodelling, modulation of cell growth, neuromuscular and immune function, and others. It has also been proposed that certain vitamin D3 analogues (e.g.
  • 25-hydroxy-vitamin-D3 or calcidiol, 1, 25-dihydroxyvitamin-D3 or calcitriol, calcipotriol; see e.g. 8 , 9 , 10 , FIG. 3 ) can be used topically to treat skin conditions, including psoriasis [see e.g. 11 , 12 , 13 , 14 ].
  • psoriasis see e.g. 11 , 12 , 13 , 14 .
  • recent studies using genetically modified mice, which exhibit altered mineral homeostasis due to a high vitamin D3 activity showed features of premature aging that include retarded growth, osteoporosis, atherosclerosis, ectopic calcification, immunological deficiency, skin and general organ atrophy.
  • Vitamin D is also involved in rebuilding the skin barrier [see e.g. 15 , FIG. 2 ], sustaining immune defence against microorganisms and protecting a healthy microflora [see e.g. 16 ], Vitamin D3 also reduce inflammation, supporting of the skin and is involved in the wound healing [see e.g. 17 - 20 ], and protecting the skin from photo damage [see e.g. 21 - 25 , FIGS. 2, 3 ]. It is presumed that throughout the local production of vitamin D in the skin together with the skin browning is the most important mechanism of skin protection against photo damage [see e.g. 26 ].
  • Hyaluronic acid is a linear polysaccharide with repeating disaccharide units composed of glucuronic acid and N-acetyl glucosamine and is one of the major matrix substances in which cells and fibrous constituents of the matrix such as collagen and elastin are embedded [see e.g. 27 , 28 , FIG. 2 ].
  • HA has an enormously high water binding capacity [see e.g. 29 ] and contributes largely to the maintenance of the extracellular space and to control tissue hydration working as a humectant [see e.g. 30 ]. It is known, that crosslinking HA polymer chains transform the HA solution into a gel.
  • Crosslinker molecules bind individual HA polymer chains to create a network, which manifests macroscopically as a gel mass. It has been suggested that HA plays a pivotal role in tissue regeneration [see e.g. 31 , 32 , FIG. 2 ].
  • vitamin D3 or a derivative or precursor thereof preferably a precursor such as 7-dehydrocholesterol (7-DHC) or a derivative thereof can be formulated in combination with HA as a stabilized colloid.
  • This colloidial carrier system shows a synergistic effect in the treatment and prevention of inflamed skin, especially photodamage of the skin, such as skin atrophy, skin dyspigmentation (patches/spots), photodermatitis (erythema: inflamed and reddened skin), telangiectasia, (couperose) and UV prevention to avoid skin erythema and actinic keratosis [ FIG. 2 ].
  • a new composition comprising vitamin D3 or a derivative or precursor thereof, preferably a precursor such as 7-DHC or a derivative thereof and HA or derivatives, optionally in combination with additional excipients, encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) to allow the penetration and localized delivery of stabilized vitamin D3 or a derivative or precursor thereof, preferably a precursor such as 7-DHC or a derivative thereof into the upper layers of the skin.
  • a lipid based colloidal carrier system preferably lipid based vesicles such as liposomes, niosomes, tranferosomes
  • the two active substances combined topically are able to act in a synergistic manner directly in the upper layers of the skin on the dominant disorders of inflamed skin, especially in photodamage, in particular on the indication according ICD-10 of sun and especially UV radiation exposed and damaged skin.
  • the new composition of the invention is able to overcome drawbacks of prior art.
  • the additional seven excipients will act synergistic with the two active substances and allow an optimal efficacy to prevent and/or treat the described skin disorders.
  • the described composition (and formulations thereof) will provide a new approach to prevent and/or treat most disorders of inflamed skin, sun and especially UV radiation damaged skin [ FIGS. 2, 3 ].
  • the invention is directed towards a new composition (also referred to as composition of the invention) comprising a synergistic combination of at least one vitamin D3 or a derivative or precursor thereof, preferably a precursor such as 7-DHC or a derivative thereof and at least one HA or derivative thereof, encapsulated in a lipid based colloidal carrier system (to allow for optimal skin penetration and stabilization of the vitamin D3 or a precursor or derivative thereof) and suitable formulations thereof.
  • a new composition also referred to as composition of the invention
  • a synergistic combination of at least one vitamin D3 or a derivative or precursor thereof preferably a precursor such as 7-DHC or a derivative thereof and at least one HA or derivative thereof
  • a lipid based colloidal carrier system to allow for optimal skin penetration and stabilization of the vitamin D3 or a precursor or derivative thereof
  • suitable formulations thereof to allow for optimal skin penetration and stabilization of the vitamin D3 or a precursor or derivative thereof
  • the vitamin D3 or a precursor or derivative thereof and in particular 7
  • the lipid based colloidal carrier system allows vitamin D3 (and inactive vitamin D3 precursors such as 7-DHC or a derivative thereof) to penetrate into the upper layers of the skin, where exerts its activity (after being converted into the active vitamin D3 upon UVA and UVB exposure).
  • the vitamin D3 is a vitamin D3 precursor such as 7-DHC or a derivative thereof
  • the composition of the invention comprises a vitamin D precursor such as 7-DHC or a derivative thereof, in combination with HA or a derivative thereof encapsulated in a lipid based colloidal carrier system.
  • the vitamin D (and in particular the vitamin D3 precursor such as 7-DHC or a derivative thereof) is preferably present in the colloidal carrier system at a final concentration of 0.01 to 0.5 wt %.
  • composition further comprises one or more, preferably 1, 2, 3, 4, 5, 6, 7 further components selected from a vitamin A (preferably retinyl palmitate), at least one vitamin B, a vitamin C (preferably L-ascorbic acid) and a vitamin E (preferably tocopheryl acetate).
  • a vitamin A preferably retinyl palmitate
  • a vitamin B preferably L-ascorbic acid
  • a vitamin E preferably tocopheryl acetate
  • the composition further comprises one or more, most preferably all, of (i) retinyl palmitate (vitamin A), (ii) riboflavin (vitamin B2), (iii) niacinamide (vitamin B3), (iv) dexpanthenol (Provitamin B5), (v) folic acid (vitamin B9), (vi) L-ascorbic acid (vitamin C) and (vii) tocopheryl acetate (vitamin E).
  • the lipid based colloidal carrier system is a liposomal carrier system (preferably a lipid based vesicle such as liposome, niosome, tranferosome) composed of at least one phospholipid and at least one fatty acid.
  • a liposomal carrier system preferably a lipid based vesicle such as liposome, niosome, tranferosome
  • the lipid based colloidal carrier system comprises one or more of e.g. lecithin, linolenic acid, linoleic acid, phosphatidylcholine and caprylic/capric triglyceride.
  • the lipid based colloidal carrier e.g. a lipid based vesicle such as liposome, niosome, tranferosome
  • the lipid based colloidal carrier comprises the synergistic combination of 7-DHC and HA in combination with the two lipophilic agents retinyl palmitate (Vitamin A), tocopheryl acetate (Vitamin E), and the five hydrophilic agents riboflavin (Vitamin B2), niacinamide (Vitamin B3), dexpanthenol (Provitamin B5), folic acid (Vitamin B9), L-ascorbic acid (Vitamin C).
  • the composition of the invention is obtained by (i) encapsulating the vitamin D3 (and in particular vitamin D3 precursor such as 7-DHC or a derivative thereof) in the oil (or lipid) phase of the lipid based colloidal carrier system at room temperatures, and (ii) separately preparing HA in the aqueous phase.
  • the compositions are obtained by emulsification of the water phase with the oil (or lipid) phase (by mixing or spontaneous integration at room temperature).
  • the particles will have a diameter of 10-500 nm, more preferably 10-300 nm, most preferably 20-150 nm.
  • composition of the invention is in form of various formulations suitable for topical or transdermal and mucosa administration.
  • topical formulations contain the pharmaceutical composition of the invention, as well as further auxiliary agents, such as buffering agents, preserving agents and the like.
  • Typical formulations include hydrogels, liogels, hydrolotions, lipolotions, cremes, ointments, and the like.
  • the invention is directed towards the use of the composition of the invention (and topical formulations thereof) in the prevention and/or treatment of skin photo damage symptoms, in particular in the prevention and/or treatment of skin atrophy, skin dyspigmentation (patches/spots), photodermatitis (erythema: inflamated and reddened skin), telangiectasia, (couperose), prevention of photodermatitis (erythema: inflammation of the skin), actinic keratosis and skin UVA and UVB protection.
  • FIG. 1 Adequate concentrations of the inactive precursor 7-DHC is transported in form of a lipid-based colloid according to the invention in the upper layers of the skin, where it is converted to active vitamin D3 upon UVA and UVB exposure.
  • FIG. 2 7-DHC in the oil (or lipid) phase and hyaluronic acid (HA) in the water phase are integrated into the colloidal carrier system, which allows the penetration into the upper layers of the skin.
  • HA hyaluronic acid
  • FIG. 3 7-DHC pathway of potent anti-inflammation activity in the upper layers of the skin after being activated to vitamin D3.
  • the invention is directed towards a new composition, hereinafter also called composition of the invention, comprising a synergistic combination of at least one vitamin D3 or a precursor or derivative thereof, preferably a precursor such as 7-dehydrocholesterol (7-DHC) or a derivative thereof, and at least one HA or derivative thereof, encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes), and suitable topical formulations thereof.
  • a lipid based colloidal carrier system preferably lipid based vesicles such as liposomes, niosomes, tranferosomes
  • topical refers to administration to any part of the skin and mucous membranes, including ocular mucous membranes.
  • photodamage refers to ICD-10 definition 2016 and is characterized as a skin disorder due to sun exposure and to radiation of UVA and UVB.
  • the term “synergistic” when used in relation to the compositions of the present invention means that the therapeutic effect of the combination of agents is greater than the sum of the effects of the individual agents in the combination.
  • vitamin D refers to any of the antirachitic forms known in the art to be suitable for nutritional use such as vitamin D 1 , vitamin D 2 , vitamin D 3 , vitamin D 4 , vitamin D 5 , vitamin D 6 , and vitamin D 7 .
  • the vitamin D preferably the vitamin D3 and its precursor 7-DHC, is used at a concentration of 10,000 IU-50,000 IE and 0.01-4 wt %. Preferable concentration of 0.01 to 3 wt %, more preferably of 0.01 to 0.75 wt %, most preferably 0.01 to 0.5 wt % of the total weight of the composition according to the present invention.
  • hyaluronic acid also known as hyaluronan, hyaluronate, or HA
  • HA hyaluronan
  • GlcNAc N-acetylglucosamine
  • GlcUA glucuronic acid
  • HA hyaluronic acid
  • HA HA or salts of HA, such as the sodium, potassium, magnesium and calcium salts, among others.
  • hyaluronic acid or “HA” includes both natural and synthetic formulas and combinations of these natural and synthetic formulas including salt forms thereof.
  • HA and its various molecular size fractions and the respective salts thereof have been used as medicaments, especially in treatment of arthropathies, as an auxiliary and/or substitute agent for natural organs and tissues, especially in ophthalmology and cosmetic surgery, and as agents in cosmetic preparations.
  • Products of HA have also been developed for use in orthopaedics, rheumatology, and dermatology.
  • High molecular weight (MW) fractions of HA having an average MW of about 1 to about 1.5 MDa are well known for providing excellent moisturizing properties in cosmetic compositions such as lotions and creams.
  • a crosslinking agent e.g. 1,4-butanediol diglycidal ether (BDDE) and the like
  • BDDE 1,4-butanediol diglycidal ether
  • HA is in form of a gel obtained by crosslinking the HA polymer chains (through the primary hydroxyl site (—CH 2 OH) and/or secondary hydroxyl sites (—CHOH) within the HA monomeric unit), with low molecular crosslinked HA showing a high water retention capacity into the skin.
  • HA for use in the present invention is preferably of low MW, e.g. 4 kDa to 50 kDa, combined with higher MW up to 200′000 kDa.
  • the HA is used at a concentration of 0.01 to 8 wt % (or 80 mg/ml), preferably of 0.01 to 5 wt % (or 50 mg/ml), more preferably of 0.01 to 4 wt % (or 40 mg/ml), most preferably 0.01 to 3 wt % (or 30 mg/ml).
  • the most preferable concentration of total HA is 3 wt %, preferably as a mixture of lowest MW HA of 4-5 kDa, low to medium or medium molecular HA of 40-50 kDa and high MW HA of 50′000-200′000 kDa (wt %).
  • the ratio of lowest molecular HA of 4-5 kDa to medium molecular HA of 40-50 kDa to high MW HA of 50′000-200′000 kDa is (1-10):(0.1-2):(0.1-2), preferably (2-6):(0.5-1.5):(0.5-1.5), most preferably about 4:about 1:about 1 (or about equal wt % of medium and highMW HA).
  • HA has a synergistic effect on the hydration of the epidermis and also on the immune protective effect [see e.g. 33 , 34 , 35 , 36 FIGS. 2, 3 ].
  • HA together with a vitamin D3 such as 7-DHC have a synergistic physico-chemical mode of action on photo damaged skin.
  • the composition of the invention comprises 7-DHC in the oil phase of the colloidal carrier system and HA as active substances in the water phase of the colloidal carrier system.
  • the two phases are obtained separately and then combined to form a lipid based colloidal carrier system.
  • 7-DHC also serves as additional activator of the further components (hereinafter also referred to as auxiliary agents), which are particularly effective in the prevention and/or treatment of photodamage.
  • compositions further comprising one or more components selected from a vitamin A (preferably retinyl palmitate), at least one vitamin B, a vitamin C (preferably L-ascorbic acid) and a vitamin E (preferably tocopheryl acetate) achieve an effective prevention and/or treatment of photodamage [see FIGS. 1, 2, 3 ].
  • composition of the invention further comprises one or more, preferably 1, 2, 3, 4, 5, 6, or 7 further components selected from a vitamin A (preferably retinyl palmitate), at least one vitamin B, a vitamin C (preferably L-ascorbic acid) and a vitamin E (preferably tocopheryl acetate).
  • a vitamin A preferably retinyl palmitate
  • a vitamin B preferably L-ascorbic acid
  • a vitamin E preferably tocopheryl acetate
  • vitamin A refers to retinol, retinal, retinoic acid, and several provitamin A carotenoids (most notably beta-carotene), preferably the major form retinyl palmitate.
  • Vitamin A and particularly retinyl palmitate absorbs light in the short-wavelength UVA range, having a photoprotective effect in the skin. It was found that retinyl palmitate showed an ad on effect together with 7-DHC with regard to absorbing short-wavelength UVA range, the down regulation of NF- ⁇ B and therefore on the UV-induced inflammation of the skin [see e.g. 36 , 37 ].
  • Retinyl palmitate diffuses into the skin, where it is partially hydrolyzed to retinol, penetrates into the stratum corneum, epidermis, and dermis and acts as a UV filter by absorbing UV radiation in the range between 300-350 nm theregy supporting the effects of the compositions of the invention.
  • retinyl palmitate is used at a concentration of 0.01 wt % up to 2 wt %, preferably 0.01 wt % to 0.5 wt %, more preferably 0.01 to 0.2 wt %, most preferably 0.01 to 0.1 wt %.
  • vitamin B refers a class of water-soluble, chemically distinct vitamins including thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), folate (B7) and various cobalamins (B12).
  • thiamine B1
  • riboflavin B2
  • niacin B3
  • pantothenic acid B5
  • pyridoxine B6
  • folate B7
  • various cobalamins B12
  • riboflavin is used at a concentration of 0.01 wt % to 2 wt %, preferably 0.01 wt % to 0.2 wt %, more preferably 0.01 wt % to 0.1 wt %, most preferably 0.01 wt % to 0.0.05 wt % of the total weight of the composition according to the present invention.
  • vitamin B refers to niacinamide.
  • Niacinamide an amide of niacin (B3), is a hydrophilic endogenous substance, which has the potential to act as an antioxidant, can improve epidermal barrier function, decrease skin hyperpigmentation, reduce skin atrophy, decrease redness/blotchiness, and improve skin elasticity [ 54 , 55 ].
  • Niacinamide shows a synergistic effect with HA in rebuilding the structural and functional integrity of the epidermal barrier function and as humectant of the epidermis [ FIG. 2 ].
  • Niacinamide controls the NF ⁇ B-mediated transcription of signalling molecules by inhibiting the nuclear poly (ADP-ribose) polymerase-1 (PARP-1).
  • PARP-1 nuclear poly (ADP-ribose) polymerase-1
  • niacinamide will have an added on effect on NF ⁇ B-mediated transcription with 7-DHC and vitamin A (particularly retinyl palmitate) [see e.g. 38 , 40 ].
  • niacinamide (vitamin B3) is used at a concentration of 0.5 wt % up to 5 wt %, preferably up to 4 wt %, more preferably up to 3 wt %, most preferably 3 wt % of the total weight of the composition according to the present invention.
  • vitamin B refers to dexpanthenol (provitamin B5).
  • Topical dexpanthenol acts like a humectant and the activity may be based on the hygroscopic properties of dexpanthenol.
  • Dexpanthenol additionally shows protective effects against skin irritation [see e.g. 39 .
  • Dexpanthenol significantly accelerates the wound healing process in children post-tonsillectomy intervention [see e.g. 36 ].
  • dexpanthenol (vitamin B5) is used at a concentration of 0.5 wt % up to 5 wt %, preferably of to 3 wt %, more preferably of 2.5 wt %, most preferably 1 wt % of the total weight of the composition according to the present invention.
  • vitamin B refers to folic acid (B9).
  • Folic acid is essential for DNA synthesis, repair and methylation, in particular nucleotide biosynthesis and remethylation of homocysteine.
  • Folic acid is essential for cellular DNA, RNA production, and is known for its use in the prevention of neural tube defects (NTDs) and serious birth defects and the treatment of anaemia caused by folic acid deficiency.
  • NTDs neural tube defects
  • Folic acid also shows in vitro and in vivo in combination with creatine a significant acceleration of the epidermal skin regeneration [see e.g. 41 ] and thus, can promote a synergistic effect together with 7-DHC covering the UV-induced cell damages and inflammation [ FIG. 2 ].
  • folic acid (Vitamin B9) is used at a concentration of 0.01 wt % up to 0.2 wt %, preferably of to 0.07 wt %, more preferably of 0.05 wt %, most preferably 0.02 wt % of the total weight of the composition according to the present invention.
  • vitamin C refers to L-ascorbic acid, which is used as a supplement to treat and prevent scurvy and erythema of the skin [see e.g. 42 , 43 ]. Scurvy leads to the formation of brown spots on the skin, spongy gums, and bleeding from all mucous membranes. L-ascorbic acid acts as an electron donor for different essential enzymes in the skin, which are required for the hydroxylation of proline and lysine in the synthesis of collagen [see e.g. 44 , 45 , 46 and the synthesis of carnitine, which is essential for the transport of fatty acids into mitochondria for ATP generation in the dermal cells [see e.g.
  • Ascorbate also acts as an antioxidant, protecting against oxidative stress [see e.g. 49 ] and is a powerful reducing agent capable of rapidly scavenging a number of reactive oxygen species (ROS) and thus, can promote a synergistic effect together with 7-DHC.
  • ROS reactive oxygen species
  • L-ascorbic acid is used at a concentration of 0.1 wt % up to 10 wt %, preferably of to 5 wt %, more preferably of 2 wt %, most preferably 3 wt % of the total weight of the composition according to the present invention.
  • vitamin E refers to compounds known as tocopherols and tocotreienols, preferably tocopheryl acetate.
  • Tocopheryl acetate can penetrate the skin to the living cells, where about 5 wt % is converted to free tocopherol.
  • Tocopheryl acetate has shown antioxidant activities and acts as a peroxyl radical scavenger, disabling the production of damaging free radicals in tissues [see e.g. 50 ] and thus can promote a synergistic effect together with 7-DHC.
  • tocopheryl acetate is used at a concentration of 0.1 wt % to 5 wt %, preferably 0.1 wt % to 5 wt %, more preferably 0.1 wt % to 3 wt %, most preferably 0.1 wt % to 2 wt % of the total weight of the composition according to the present invention.
  • the composition of the invention comprising 7-DHC and HA further comprises one or more components selected from retinyl palmitate, riboflavin, niacinamide, dexpanthenol, folic acid, L-ascorbic acid and tocopheryl acetate, encapsulated in a lipid based colloidal carrier system.
  • the composition of the invention comprises 7-DHC and HA as well as a combination of components as follows:
  • vitamin E Niacinamide and dexpanthenol or niacinamide and folic acid or niacinamide and L-ascorbic acid or niacinamide and tocopheryl acetate
  • compositions (and topical formulations of the invention comprising 7-DHC and HA further comprise the components retinyl palmitate, riboflavin, niacinamide, dexpanthenol, folic acid, L-ascorbic acid and tocopheryl acetate encapsulated in a lipid based colloidal carrier system.
  • concentrations and ranges of concentrations are described as follows in Table 1.
  • lipid based colloidal carrier (or “colloid”) as used herein refers well known particulate carrier systems, preferably spherical vesicles having at least one lipid bilayer.
  • Typical colloidal carriers include liposomes, niosomes, transferosomes, micelles, nanoparticles, microemulsions and others, preferably liposomes, niosomes, transferosomes, most preferably liposomes.
  • the lipid based colloidal carrier system is in form of: (a) multilamellar vesicles (MLV), (b) large unilamellar vesicles (LUV), (c) small unilamellar vesicles (SUV), (d) multivesicle vesicles (MW), oligolamellar vesicles (OLV).
  • MLV multilamellar vesicles
  • LUV large unilamellar vesicles
  • SUV small unilamellar vesicles
  • MW multivesicle vesicles
  • OSV oligolamellar vesicles
  • the preferred particle size ranges from 10-500 nm, preferably 10 to 300 nm, more preferably 20-150 nm.
  • the colloids are based on natural and/or synthetic phospholipids and compose typically 10 wt % of the formulation.
  • phospholipids include fatty acids having a phosphate-containing polar endgroup which is hydrophilic and thus soluble in water, and a hydrophobic end group, which is soluble in fats joined together by a glycerol molecule (e.g. glycerophospholipids) or sphingosine molecule (e.g. phosphosphingolipids).
  • the phospholipids used in the colloidal carrier system include one or more of phosphatidylcholine, lysophosphotidylcholine, hydrogenated phospholipids, and unsaturated phospholipids.
  • glycerophospholipids include phosphatidic acid (phosphatidate) (PA), phosphatidylethanolamine (cephalin) (PE), phosphatidylcholine (lecithin) (PC), Phosphatidylserine (PS), and Phosphoinositides, which further include phosphatidylinositol (PI), phosphatidylinositol phosphate (PIP), phosphatidylinositol bisphosphate (PIP2), and phosphatidylinositol triphosphate (PIP3).
  • PA phosphatidic acid
  • PE phosphatidylethanolamine
  • PC phosphatidylcholine
  • PS Phosphatidylserine
  • phosphosphingolipids examples include ceramide phosphorylcholine (sphingomyelin) (SPH), ceramide phosphorylethanolamine (sphingomyelin) (Cer-PE), and ceramide phosphorylglycerol.
  • the colloidal carrier system of the invention may further comprise fatty acids such as omega-3, omega-6 and omega-9 fatty acids.
  • Preferred examples used in the present invention are lecithin, sphingomyeline, phosphatidylcholine, linoleic acid, linolenic acid, caprylic acid, capric acid, Lupinus albus seed oil, Squalene, Imidazolidinyl Urea and Sodium Ascorbyl Phosphate.
  • a preferred embodiment of a lipid based colloidal carrier system is shown in Table 2.
  • the colloidal carrier system can also include a polycarbonate, a Polyvinylpyrrolidon (PVP), also Polyvidon or Povidonmembranes, preferably copovidone of a MW 10 nm-500 nm. Copovidone will be used as film-forming agent and binder and also as carrier system.
  • PVP Polyvinylpyrrolidon
  • Copovidone will be used as film-forming agent and binder and also as carrier system.
  • the lipophilic agents will be encapsulated within the bilayer system, whereas the hydrophilic agents will be encapsulated in the aqueous phase of the system.
  • the vitamin D precursor such as 7-DHC or a derivative thereof
  • the phospholipid(s) and optional additional lipophilic agents e.g. retinyl palmitate and tocopheryl acetate
  • the HA and optional additional hydrophilic agents are mixed together separately in an aqueous solution.
  • the aqueous solution comprising HA and optional additional hydrophilic agents are mixed to the oil phase comprising the vitamin D precursor (such as 7-DHC or a derivative thereof).
  • the hydrophilic components (HA and additional hydrophilic agents) of the compositions are present in aqueous compartments while the lipophilic components of the compositions already insert themselves with the first step in phospholipid bilayers of the particles.
  • the lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) is composed of lecithin, linolenic acid, linoleic acid, phosphatidylcholin and paprylic/papric triglyceride, which is charged with the components Vitamin D3, such as 7-DHC or a derivative thereof, and HA and optionally at least one, preferably 1, 2, 3, 4, 5, 6 or 7 of the components retinyl palmitate, riboflavin, niacinamide, dexpanthenol, folic acid, L-ascorbic acid and tocopheryl acetate.
  • the uniquely charged and stable carrier system will allow penetrating the skin in the upper layers of the skin to allow the synergistic compositions of the invention to take effect directly at the desired site.
  • compositions of the invention may further comprise one or more pharmaceutically acceptable additives, excipients, adjuvants commonly used in formulations used for application to the skin and/or mucous membranes.
  • Typical additives include e.g. a relevant UV filter system or one or more UVA/B protectants for prevention of photodamage and sun UVA and UVB protection such as Fillagrine trans-Urocanin Acide, Butyl Methoxydibenzoylmethane Neo Heliopan 357 Eusolex 9020, Parsol 1789, Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano), Tinosorb M, Ethylhexyl Triazone Uvinul T 150, Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine Tinosorb S, Ethylhexyl Methoxycinnamate Uvinul MC 80, Parsol MCX, Neo Heliopan AV 4, and the like.
  • the UV filter(s) are embedded with the active ingredients and auxiliary ingredients for the prevention of skin erythema and actinic keratosis, or other forms of non melanoma skin cancer (NMSC).
  • Typical adjuvants include e.g. surfactants, emulsifying agents, emollients, thickening agents, conditioning conservants, buffering agents, humectants, perfuming agents, and the like.
  • the carrier system may further comprise one or more surfactants.
  • surfactant refers to a material which lowers the surface tension of a liquid and the interfacial tension between two liquids, allowing their easier spreading. Surfactants have a hydrophilic head that is attracted to water molecules and a hydrophobic tail that repels water and simultaneously attaches itself to oil and grease in dirt.
  • surfactant agents include, but are not limited to, non-ionic, ionic (either anionic or cationic) or zwitterionic (or amphoteric wherein the head of the surfactant contains two oppositely charged groups) surfactants.
  • anionic surfactants include, but are not limited to, those based on sulfate, sulfonate or carboxylate anions such as perfluorooctanoate (PFOA or PFO), alkyl benzene sulfonate, soaps, fatty acid salts, or alkyl sulfate salts such as perfluorooctanesulfonate (PFOS), sodium dodecyl sulfate (SDS), ammonium lauryl sulfate, or sodium lauryl ether sulfate (SLES).
  • PFOA or PFO perfluorooctanoate
  • SDS sodium dodecyl sulfate
  • SLES sodium lauryl ether sulfate
  • cationic surfactants include, but are not limited to, those based on quaternary ammonium cations such as or alkyltrimethylammonium including cetyl trimethylammonium bromide (CTAB) a.k.a., or hexadecyl trimethyl ammonium bromide, cetylpyridinium chloride (CPC), polyethoxylated tallow amine (POEA), benzalkonium chloride (BAC), or benzethonium chloride (BZT).
  • CTAB cetyl trimethylammonium bromide
  • CPC cetylpyridinium chloride
  • POEA polyethoxylated tallow amine
  • BAC benzalkonium chloride
  • BZT benzethonium chloride
  • zwitterionic surfactants include, but are not limited to dodecyl betaine, cocamidopropyl betaine, or coco ampho glycinate.
  • non-ionic surfactants include, but are not limited to, alkyl poly(ethylene oxide), alkylphenol poly(ethylene oxide), copolymers of poly(ethylene oxide), poly(propylene oxide) (commercially called Poloxamers or Poloxamines), alkyl polyglucosides including octyl glucoside and decyl maltoside, fatty alcohols including cetyl alcohol and oleyl alcohol, cocamide MEA, cocamide DEA, or polysorbates including tween 20, tween 80, or dodecyl dimethylamine oxide.
  • alkyl poly(ethylene oxide) alkylphenol poly(ethylene oxide), copolymers of poly(ethylene oxide), poly(propylene oxide) (commercially called Poloxamers or Poloxamines)
  • alkyl polyglucosides including octyl glucoside and decyl maltoside
  • fatty alcohols including cetyl alcohol and oleyl alcohol
  • cocamide MEA cocamide DEA
  • the surfactant is foaming and skin friendly, including polysorbates, such as polysorbate 20 or 40, coco glucoside, lauryl glucoside, decyl glucoside, lauryl sulfates such as ammonium, sodium, magnesium, MEA, triethylamine (TEA), or mipa lauryl sulfate, cocamidopropyl betain, or sodium alkyl sulfosuccinates.
  • polysorbates such as polysorbate 20 or 40, coco glucoside, lauryl glucoside, decyl glucoside, lauryl sulfates such as ammonium, sodium, magnesium, MEA, triethylamine (TEA), or mipa lauryl sulfate, cocamidopropyl betain, or sodium alkyl sulfosuccinates.
  • polysorbates such as polysorbate 20 or 40, coco glucoside, lauryl glucoside, decy
  • the surfactant is at least one polysorbate, e.g. polysorbate 10-150, which are non-ionic surfactants commonly used as excipients and emulsifiers.
  • the polysorbate is a polysorbate-type nonionic surfactant formed by the ethoxylation of sorbitan before the addition of lauric acid as Scattics, PS20 as Alkest TW 20 and Tween 20.
  • Polysorbates have efficiency in the stabilization of the colloidal carrier and in the presence of liquid lipids with different fatty acid C-chains produces with less organized crystalline structure can provides better loading capacity for active substance accommodation. The effect of polysorbate will be in the stabilization the carrier system through the physiochemical properties of the formulated nanoparticles.
  • the colloidal carrier system are stabilized with polysorbate like polysorbate 20 or polysorbate 80.
  • Polysorbate will be used as better dispersing agent for the liposomal carrier system.
  • the small size and superior particle surface to volume ratio would increase loading efficiency and bioavailability of the active substance, thus making the liposomal carrier system a more efficient delivery system.
  • the surfactant is polyvinylpyrrolidone (PVP), which is known to either prevent precipitation or reduce the size of the resulting particles of the active ingredients or auxiliary substances with strongly pH-dependent aqueous solubility.
  • PVP polyvinylpyrrolidone
  • the PVP like poloxamer/copovidone will be used to stabilize particles in the liposomal formulation. It is presumed, that the dissolution efficiency is higher with Polyvinylpyrrolidone (PVP) and is increased with increased polymer concentration. PVP is typically used as stabilisation and to increase efficiency and bioavailability of the liposomal carrier system.
  • the carrier system may further compromise a polycarbonate, Polyvinylpyrrolidon (PVP), Polyvidon, Povidonmembranes, Povidone, Copovidone, Hypromellose and Eudragit EPO, preferably Copovidone of a MW 10 nm-500 nm.
  • PVP Polyvinylpyrrolidon
  • Polyvidon Polyvidon
  • Povidonmembranes Povidone
  • Copovidone preferably Copovidone of a MW 10 nm-500 nm.
  • the amount of the surfactant in the compositions of the present invention is between 0.5 and 10 wt % of the total weight of the composition according to the present invention.
  • emollient agent refers to an agent that softens and soothes the skin in order to correct dryness and scaling of the skin, lubricating the skin surface, encouraging skin water retention, and altering product textures.
  • topical emollient agents include, but are not limited to, octyl hydroxystearate, lanolin, caprylic/capric triglyceride, cetyl palmitate, octyldodecanol, cetyl alcohol, isopropyl isostearate, glyceryl dilaurate, isopropyl myristate, palm alcohol, dimethicone, squalane, plukenetia volubilis seed oil, butyrospermum parkii butter, sucrose cocoate, or their mixtures.
  • the emollient is selected from the group consisting of dimethicone, squalane, plukenetia volubilis seed oil, butyrospermum parkii butter, caprylic/capric triglyceride, octyldodecanol, or their mixtures.
  • the amount of emollient agent in the compositions of the present invention is between 10 and 30 wt % of the total weight of the composition according to the present invention.
  • humectant agent refers to a hygroscopic agent which attracts water molecules from the surrounding environment though either absorption or adsorption, preventing the skin from losing moisture.
  • topical humectants include, but are not limited to, glycerin, diglycerin, ethylhexylglycerin, glucose, honey, lactic acid, polyethylene glycol, propylene glycol, sorbitol, sucrose, or threalose.
  • the humectant is selected group consisting of glycerin, diglycerin, ethylhexylglycerin, and their mixtures.
  • the amount of the humectants in the compositions of the present invention is between 0.5-15 wt %, preferably 0.5-10 wt %, of the total weight of the composition according to the present invention.
  • thickening agent or “thickener” or “viscosity agent” which is herein used interchangeably refers to a material that increases its viscosity without substantially modifying its other properties.
  • appropriate viscosity agents include, but are not limited to, cellulose or their derivatives such as hydroxypropyl methylcellulose, polyethylene glycol, microcrystalline cellulose, cetearyl alcohol, alginates, branched polysaccharides, fumed silica, xanthan gum, carbomer, and polyacrylates.
  • the viscosity agent is selected group consisting of microcrystalline cellulose, cetearyl alcohol, cellulose, xanthan gum, and carbomer.
  • the amount of the viscosity agents in the compositions of the present invention is between 0.5 and 15 wt %, preferably 0.5-10 wt %, of the total weight of the composition according to the present invention.
  • emulsifying agent or “emulsifier” which is herein used interchangeably refers to a material that reduces surface tension, promoting the formation of intimate mixtures of non-miscible liquids by altering the interfacial tension. Emulsifier stabilizes an emulsion by increasing its kinetic stability.
  • emulsifier examples include, but are not limited to, glyceryl trioleate, glyceryl oleate, acetylated sucrose distearate, sorbitan trioleate, polyoxyethylene monostearate, glycerol monooleate, sucrose distearate, polyethylene glycol monostearate, octyl phenoxypoly (ethyleneoxy) ethanol, deacylerin penta-isostearate, sorbitan sesquioleate, hydroxylated lanolin, lecithin, lanolin, triglyceryl diisostearate, polyoxyethylene oleyl ether, calcium stearoyl-2-lactylate, sodium lauroyl lactylate, sodium stearoyl lactylate, cetearyl glucoside, methyl glucoside sesquistearate, sorbitan monopalmitate, methoxy polyethylene glycol-22/dodecyl glycol copolymer
  • the emulsifier is selected group consisting of glyceryl oleate, lecithin, sodium lauroyl lactylate, sodium stearoyl lactylate, glyceryl stearate, candelilla/jojoba/rice bran polyglyceryl-3 esters, and their mixtures.
  • the amount of the emulsifier in the compositions of the present invention is between 0.5 and 15 wt %, preferably 0.5-10 wt %, of the total weight of the composition according to the present invention.
  • pH-regulating agent refers to acids or bases that can be used to adjust the pH of the finished product to the desired level, without affecting the stability of the solution.
  • appropriate topical pH-regulating agents include, but are not limited to, acetic acid, lactic acid, citric acid, gluconic acid, ethanolamine, formic acid, oxalic acid, tartaric acid, potassium hydroxide, sodium hydroxide, triethanolamine, or their mixtures.
  • the pH-regulating agent is selected group consisting of triethanolamine, sodium hydroxide, lactic acid, and citric acid.
  • the amount of the pH-regulating agent in the compositions of the present invention is between 0.01 and 1 wt % of the total weight of the composition according to the present invention.
  • condition conservant refers to a compound that has a moisturizing function, more specifically a compound that acts on the barrier function, for the purpose of keeping the stratum corneum moisturized, such as ceramides, sphingoid-based compounds, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, ⁇ -sitosterol or campesterol), essential fatty acids, 1,2-diacylglycerol, 4-chromanone, pentacyclic triterpenes, petroleum jelly and lanolin; or a compound which directly increases the water content of the stratum corneum, such as threalose and its derivatives, glycerol, pentanediol, pidolates, serine, xylitol, peroxyethanol, sodium lactate, glyceryl polyacrylate, ectoin and its derivatives, chitosan, oligo- and polysaccharide
  • perfuming agent refers to any perfume or aroma which is capable of releasing an agreeable odor.
  • the perfuming substance contained in the compositions of the invention may derive from perfumes and aromas of natural or synthetic origin and mixtures thereof.
  • perfumes and aromas of natural origin are flower extracts (lily, lavender, rose, jasmine, ylang-ylang), stems and leaves (patchouli, geranium, bitter leaf), fruits (coriander, anis, cumin, juniper), fruit skin (bergamot, lemon, orange), roots ( angelica , celery, cardamom, iris, sweet flag), wood (pinewood, sandalwood, lignum vitae, pink cedar), herbs and graminaceae (tarragon, lemon grass, sage, thyme), needles and branches (spruce, fir, pine, dwarf pine), resins and balsams ( galbanum , gum elemi, gum benzoin, myrrh, frankinc
  • the quantity of perfuming agents is from 1 wt % to 30 wt % by weight, more preferably 2 wt % to 25 wt % by weight with respect to the total composition weight.
  • a preferred composition is shown in Table 3.
  • Lipid based colloidal carrier system e.g. lipid based vesicles such as liposomes, niosomes, tranferosomes
  • lipid based carrier systems in general, see e.g. Liposomes, eds. Angel Catala, pub. InTech, 2017 (ISBN 978-953-51-3580-7), or of liposomal carriers see e.g. Liposomes, Methods and Protocols, Springer Protocols, eds. D'Souza, Gerard G. M., 2017).
  • the colloid can be formed by any conventional technique for preparing multilamellar lipid vesicles (MLVs), that is, by placing the lipophilic vitamin D3 or precursor thereof with one or more lipids in a suitable vessel, dissolving the lipids in an organic solvent, e.g. chloroform, and evaporating the organic solvent to obtain a lipid film.
  • an organic solvent e.g. chloroform
  • hydration of the lipid film is achieved by adding an aqueous solution containing the hydrophilic components including the hyaluronic acid.
  • the obtained lipid suspension is subjected to swirling or vortexing to give the final composition according to the invention.
  • the liposomes can be in the form of steroidal lipid vesicles, stable plurilamellar lipid vesicles (SPLVs), monophasic vesicles (MPVs), or lipid matrix carriers (LMCs).
  • SPLVs stable plurilamellar lipid vesicles
  • MPVs monophasic vesicles
  • LMCs lipid matrix carriers
  • the liposomes can be subjected to multiple (five or more) freeze-thaw cycles to enhance their trapped volumes and trapping efficiencies and to provide a more uniform interlamellar distribution of solute.
  • the liposomes are for example prepared by hot high pressure homogenization to reach high encapsulation efficiency (EE).
  • EE encapsulation efficiency
  • the encapsulation efficiency will give the percentage of active substance that is successfully entrapped/adsorbed into nanoparticles and will be carried into the depper layers of the skin.
  • NLCs nanostructured lipid carriers
  • LC limited loading capacity
  • EE encapsulation efficiency
  • the phase transfer temperature from the gel form to the crystalline two dimensional grid states with less mobility in a fluid crystalline structure is depending of the head group, chain lengths and the saturation level esters of fatty acids.
  • the temperature will be from ⁇ 20° C. to 60° C. and can be established with the thermoanalytic methods.
  • Embedded in the fluid crystalline phase the mobility of the lipophilic agents increases and can exchange the place within the lipid layers, but not abandon the lipid layers [ 46 ].
  • the physical structure of the multilamellar layer system will be created throughout interactions between the phospholipids and the aqueous medium with the high pressure homogenisation and dehydration of dry lipids. With this method multilamellar vessels (MLV) are built.
  • MLV multilamellar vessels
  • the polycarbonate membranes of a size 10-500 nm will be used for the liposomes extrusion.
  • the homogenisation and size will be determined throughout the pore diameter of the filter and the number of the extrusion steps. Aim will be to reach the highest encapsulation efficiency.
  • this carrier system has unique physicochemical properties, such as ultra-small size (small particles from 1-100 nm dimension range), large surface area to mass ratio, and high reactivity, which are different from bulk materials of the same composition. These properties are being used to overcome the limitation of skin penetration with larger size of molecules and encapsulate as needed lipophilic and hydrophilic substances to pass the skin barrier.
  • compositions of the invention are directed towards suitable formulations of the compositions of the invention for topical or transdermal application.
  • compositions of this invention can be used in different types of topical or transdermal applications, which may be in solid, liquid or semisolid form.
  • suitable formulations include, but are not limited to, emulsions (e.g. oil and/or silicone in water emulsions, water-in-oil and/or silicone emulsions, water/oil/water or water/silicone/water type emulsions, and oil/water/oil or silicone/water/silicone type emulsions), microemulsions, aqueous dispersions, oils, milks, balsams, foams, aqueous or oily lotions, aqueous or oily gels, creams, solutions, hydroalcoholic solutions, hydroglycolic solutions, hydrogels, serums, ointments, mousses, pastes, sprays or aerosols, as well as inclusion of the compositions of the invention in any transdermal patches.
  • emulsions e.g. oil and/or silicone in water
  • compositions of the invention are embedded, if desired, in combination with penetration reinforcing agents and/or crystallisation inhibitors.
  • the compositions are in form of a cream or a gel or a lotion
  • the compositions are in form of transdermal therapeutic system, such as a patch or pad.
  • the invention is directed towards the use of the composition (and formulations thereof) of the invention in the prevention and/or treatment of skin photo damage symptoms, in particular in the prevention and/or treatment of skin atrophy, skin dyspigmentation (patches/spots), photodermatitis (erythema: skin inflammation and redness), telangiectasia, (couperose) and prevention of actinic keratosis, as well to protect the skin from the sun, UVA and UVB radiation.
  • the present invention contemplates a method of prevention and/or treatment of photodamage of the skin of a subject comprising administering a composition (and topical formulations thereof) of the invention to the subject in an amount effective to stop the photodamage process, i.e. to inhibit reactive oxygen species ROS, hyperoxide O-2 and nitric oxide (NO), and therefore accumulation of cytotoxic peroxynitrite (ONOO—).
  • a composition and topical formulations thereof of the invention to the subject in an amount effective to stop the photodamage process, i.e. to inhibit reactive oxygen species ROS, hyperoxide O-2 and nitric oxide (NO), and therefore accumulation of cytotoxic peroxynitrite (ONOO—).
  • compositions may be either administered at regular intervals as needed (e.g., once, twice or several times a day) or in an essentially continuous manner (e.g. via a transdermal patch).
  • HA (2% low molecular 4 KDa 96.8% of purity, 0.5 wt % of medium molecular 48.3 KDa 97.3% purity and 0.5 wt % of high molecular 1.78 ⁇ 10 6 Da eye drop grade of purity 100%) was dispersed/dissolved under stirring in water and added under stirring at room temperature separately. HA mixtures were added to the phospholipids colloids already charged with 7-DHC and stirred for 20 minutes at room temperature to obtain spontaneous formation of a homogeneous hydrogel. The microscopic analysis showed spheric particles of 20-150 nm size. The hydrogel was macroscopic and according to HPLC analysis stable showing the same concentration of added 7-DHC over 6 months.
  • lipid phase 7-DHC of purity 98.7% (hplc; area %) was used (liquefied at temperatures between 140 and 150° C.).
  • Propylenglycol was used as the organic solvent for the 7-DHGC and the phospholipids.
  • HA in form of a mixture of 2% low molecular 4 KDa 96.8% of purity, 0.5 wt % of medium molecular 48.3 KDa 97.3% purity and 0.5 wt % of high molecular 1.78 ⁇ 10 6 Da eye drop grade of purity 100% was used for the aqueous phase.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
US16/496,291 2017-03-24 2018-03-23 Pharmaceutical compositions Abandoned US20200046627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH3862017 2017-03-24
CH00386/17 2017-03-24
PCT/EP2018/057416 WO2018172511A1 (fr) 2017-03-24 2018-03-23 Compositions pharmaceutiques

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/057416 A-371-Of-International WO2018172511A1 (fr) 2017-03-24 2018-03-23 Compositions pharmaceutiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/523,661 Continuation US12178900B2 (en) 2017-03-24 2021-11-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
US20200046627A1 true US20200046627A1 (en) 2020-02-13

Family

ID=58464118

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/496,291 Abandoned US20200046627A1 (en) 2017-03-24 2018-03-23 Pharmaceutical compositions
US17/523,661 Active 2038-11-07 US12178900B2 (en) 2017-03-24 2021-11-10 Pharmaceutical compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/523,661 Active 2038-11-07 US12178900B2 (en) 2017-03-24 2021-11-10 Pharmaceutical compositions

Country Status (10)

Country Link
US (2) US20200046627A1 (fr)
EP (1) EP3600563B1 (fr)
JP (2) JP7169003B2 (fr)
KR (1) KR102560269B1 (fr)
CN (1) CN110430923A (fr)
AU (1) AU2018238691B2 (fr)
CA (1) CA3051787A1 (fr)
EA (1) EA201991766A1 (fr)
SG (1) SG11201908652QA (fr)
WO (1) WO2018172511A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114848536A (zh) * 2022-05-13 2022-08-05 上海好肌茵生物科技有限公司 皮肤光损伤修护组合物、其制备方法以及应用
WO2023135135A1 (fr) * 2022-01-11 2023-07-20 Gpq S.R.L. Nouveaux dérivés d'acides hyaluroniques en tant que combleurs innovants
WO2023156768A1 (fr) * 2022-02-16 2023-08-24 Dr Weller Limited Compositions pour la production de vitamine d
WO2024033173A1 (fr) * 2022-08-09 2024-02-15 Unilever Ip Holdings B.V. Composition photoprotectrice
WO2024137921A1 (fr) * 2022-12-22 2024-06-27 Ads Therapeutics Llc Compositions et procédés de réticulation de protéines structurales
WO2024223513A1 (fr) * 2023-04-27 2024-10-31 Beiersdorf Ag Préparation cosmétique contenant du rétinol présentant une bonne compatibilité avec la peau
US12178900B2 (en) 2017-03-24 2024-12-31 Joyderma Ag Pharmaceutical compositions
WO2025003367A1 (fr) * 2023-06-30 2025-01-02 Clariant International Ltd Composition de vitamine destinée à être utilisée dans des formulations cosmétiques

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107673324A (zh) * 2017-11-03 2018-02-09 桂林电子科技大学 一种氮掺杂的碳纳米管的制备方法
GR1009780B (el) * 2019-02-08 2020-07-06 Κωνσταντινα Δημητριου Καρυδη Συνθεση καλλυντικων σκευασματων με βαση τα εγκλεισμενα σε σωματιδια ή μη υαλουρονικα οξεα επιλεγμενων μοριακων βαρων
MY201184A (en) * 2019-09-03 2024-02-08 Malaysian Palm Oil Board A sustained release hydrogel composition
IT201900021849A1 (it) * 2019-11-21 2021-05-21 Bf Res S R L Lente a contatto morbida e confezione comprendente tale lente a contatto
CN111249302A (zh) * 2020-03-12 2020-06-09 李鑫荣 一种透明质酸片段的新应用及稳定制造方法
WO2021212267A1 (fr) * 2020-04-20 2021-10-28 L'oreal Composition pour le soin de la peau
KR20230016199A (ko) 2020-05-22 2023-02-01 아우로 파마슈티칼스 인코퍼레이티드 글루타티온을 포함하는 조성물 및 치료 방법
US20240299378A1 (en) * 2021-02-25 2024-09-12 Exinov Emulsion for use in the treatment of rosacea
KR102829946B1 (ko) * 2022-05-25 2025-07-04 주식회사 코스메카코리아 7-데하이드로콜레스테롤을 포함하는 니오좀, 이를 유효성분으로 함유하는 화장료 조성물, 및 이의 제조방법
CA3252543A1 (fr) * 2022-06-03 2023-12-07 Colgate-Palmolive Company Compositions de soins cutanés et méthodes d'utilisation
US12201717B2 (en) 2022-10-31 2025-01-21 Skinfix Inc. Compositions and methods for supporting skin barrier homeostasis
FR3151481A1 (fr) 2023-07-28 2025-01-31 Horus Pharma Emulsion de type huile dans eau comprenant de l’acide hyaluronique et du dexpanthenol
WO2025056416A1 (fr) 2023-09-11 2025-03-20 Dsm Ip Assets B.V. Particules à base de matrice lipidique

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004175731A (ja) * 2002-11-28 2004-06-24 Noevir Co Ltd 老化防止用皮膚外用剤
CN101287455A (zh) * 2005-04-01 2008-10-15 Zymes有限公司 使用CoQ10作为递送系统的皮肤浓缩物
US9173835B2 (en) * 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
ES2661728T3 (es) * 2005-10-03 2018-04-03 Pinksky, Mark A. Composiciones y métodos para el cuidado mejorado de la piel
US9265792B2 (en) * 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
US20080145415A1 (en) * 2006-04-21 2008-06-19 Lanfranco Callegaro Bioresorbable Fillers Constituted by Phospholipid Liposomes and Hyaluronic Acid and/or the Derivatives Thereof
MX337408B (es) * 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
EP2218447B1 (fr) * 2008-11-04 2017-04-19 PharmaSol GmbH Compositions contenant des micro ou nanoparticules lipides pour l'amélioration de l'action dermique de particules solides
EP2228052A1 (fr) * 2009-03-09 2010-09-15 Coty Deutschland GmbH Composition basique cosmétique et utilisation associée
US20110262505A1 (en) * 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
US20120201871A1 (en) * 2011-02-07 2012-08-09 Professional Compounding Centers Of America, Ltd. Permeation enhancers with liposomes for topical formulations
TWI466675B (zh) 2011-09-16 2015-01-01 Univ China Medical 用於抑制發炎之醫藥組合物
US8968790B2 (en) * 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
DE102014200109A1 (de) * 2014-01-08 2015-07-09 Wolfgang ANDRES-FISCHER Pharmazeutische Zusammensetzung zur Behandlung von Borreliose
ITUB20153699A1 (it) 2015-09-17 2017-03-17 Fastmeditalia Srl Integratore orale
KR102560269B1 (ko) 2017-03-24 2023-07-28 조이더마 아게 약제학적 조성물

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12178900B2 (en) 2017-03-24 2024-12-31 Joyderma Ag Pharmaceutical compositions
WO2023135135A1 (fr) * 2022-01-11 2023-07-20 Gpq S.R.L. Nouveaux dérivés d'acides hyaluroniques en tant que combleurs innovants
WO2023156768A1 (fr) * 2022-02-16 2023-08-24 Dr Weller Limited Compositions pour la production de vitamine d
CN114848536A (zh) * 2022-05-13 2022-08-05 上海好肌茵生物科技有限公司 皮肤光损伤修护组合物、其制备方法以及应用
WO2024033173A1 (fr) * 2022-08-09 2024-02-15 Unilever Ip Holdings B.V. Composition photoprotectrice
WO2024137921A1 (fr) * 2022-12-22 2024-06-27 Ads Therapeutics Llc Compositions et procédés de réticulation de protéines structurales
WO2024223513A1 (fr) * 2023-04-27 2024-10-31 Beiersdorf Ag Préparation cosmétique contenant du rétinol présentant une bonne compatibilité avec la peau
WO2025003367A1 (fr) * 2023-06-30 2025-01-02 Clariant International Ltd Composition de vitamine destinée à être utilisée dans des formulations cosmétiques

Also Published As

Publication number Publication date
EP3600563B1 (fr) 2025-09-10
SG11201908652QA (en) 2019-10-30
EA201991766A1 (ru) 2019-12-30
JP2020515635A (ja) 2020-05-28
JP7169003B2 (ja) 2022-11-10
JP2023002724A (ja) 2023-01-10
AU2018238691A1 (en) 2019-08-15
CN110430923A (zh) 2019-11-08
EP3600563C0 (fr) 2025-09-10
CA3051787A1 (fr) 2018-09-27
EP3600563A1 (fr) 2020-02-05
US12178900B2 (en) 2024-12-31
AU2018238691B2 (en) 2023-11-02
WO2018172511A1 (fr) 2018-09-27
US20220124572A1 (en) 2022-04-21
JP7265298B2 (ja) 2023-04-26
KR20190129059A (ko) 2019-11-19
KR102560269B1 (ko) 2023-07-28

Similar Documents

Publication Publication Date Title
US12178900B2 (en) Pharmaceutical compositions
CN112891241B (zh) 一种靶向线粒体皮肤抗衰纳米组合物及其制备方法和应用
CN101820849B (zh) 局部施用性化妆品或药物组合物
JP2018012738A (ja) ヒアルロン酸の皮膚濃度を増加させるための局所製剤
CN103221028B (zh) 含有齐墩果酸的化妆品组合物
PL205598B1 (pl) Środek zawierający ekstrakt z cebuli, sposób wytwarzania środka i zastosowanie środka
KR20130134532A (ko) 피부 자극 완화 및 피부 장벽 회복을 위한 다중층 액정 베지클 및 이를 포함하는 화장료 조성물
KR100752990B1 (ko) 나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
KR102078667B1 (ko) 7-데하이드로콜레스테롤, 콜레스테롤 및 스테아린산이 히알루론산-세라마이드 엔피 복합체의 내상에 봉입된 나노에멀젼을 함유하는 화장료 조성물 및 그의 제조방법
KR20180131876A (ko) 리포좀 기술을 이용한 안정화된 세라마이드 복합물 및 그 제조 방법 및 이를 함유하는 화장료 조성물
ES2804029T3 (es) Composición que contiene ácido graso poliinsaturado
KR101732844B1 (ko) 국소 피부 전달용 항염증 지질 나노 전달체를 포함하는 피부염 치료 또는 예방용 조성물
EP2769709A1 (fr) Mélange complexe de pseudo-lipide et composition pour application externe cutanée contenant celui-ci
Chamsai et al. Development of radish extract-loaded transfersomes blended sunscreen formulation for tyrosinase melanin and photoprotective sunscreening effect
EP1965758A2 (fr) Compositions contenant des proteines pour le transfert/recyclage de lipides structuellement modifies et leurs applications
ES3055015T3 (en) Pharmaceutical compositions comprising vitamin d3 and hyaluronic acid
Ricci et al. Liposome-based antioxidant delivery systems for skin health
HK40010497A (en) Pharmaceutical compositions
EA043968B1 (ru) Фармацевтическая композиция для предупреждения и/или лечения нарушений состояния кожи, состав на ее основе и их применение
KR20150078137A (ko) 주름 개선용 화장료 조성물의 제조방법
KR20260056916A (ko) 세라마이드를 포함하는 에멀전
EP1676561A2 (fr) Compositions contenant un système polyphasé biocatalytique et son utilisation
HK1157225B (en) Compositions and methods for skin care
HK1157225A1 (en) Compositions and methods for skin care
HK1197728A (en) Pseudolipid complex mixture and a skin external application composition containing same

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: JOYDERMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALBARANO, TEO;REEL/FRAME:058349/0409

Effective date: 20211205

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION